olaparib
astrazeneca
['ovarian', 'brca', 'olaparib']
from #esmo22: olaparib maintenance can provide a clinical benefit for up to 7 years in patients with brca-mutated, advanced ovarian cancer, new data suggest. 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.